help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pacifici, R.
Right arrow Articles by Kimble, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pacifici, R.
Right arrow Articles by Kimble, R. B.

Journal of Clinical Endocrinology & Metabolism, Vol 77, 1135-1141, Copyright © 1993 by Endocrine Society


ARTICLES

Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/progesterone therapy

R Pacifici, JL Vannice, L Rifas and RB Kimble
Division of Bone and Mineral Disease, Washington University School of Medicine, St. Louis, Missouri 63110.

Interleukin-1 (IL-1), a potent stimulant of bone resorption, has been implicated in the pathogenesis of postmenopausal osteoporosis, because monocyte IL-1 bioactivity increases after the menopause and is decreased by estrogen and progesterone (EP) replacement. As IL-1 bioactivity reflect the production of both IL-1 and the IL-1 inhibitor, IL-1 receptor antagonist (IL-1ra), EP treatment could decrease IL-1 bioactivity by regulating the secretion of either IL-1 or IL-1ra. We now report that EP treatment in vivo decreased the secretion into the medium of cultured monocytes of IL-1ra and IL-1 beta as well as the IL- 1 beta/IL-1ra ratio. We also found that in normal women the production of IL-1ra was within premenopausal levels in the first 7 yr after the menopause and increased linearly thereafter. In these women, monocyte IL-1 beta, IL-1 beta/IL-1ra ratio, and IL-1 bioactivity were all increased in the first 7 yr after the menopause and within the premenopausal range thereafter. In osteoporotic women, IL-1 beta, IL-1 beta/IL-1ra ratio, and IL-1 bioactivity increased after the menopause and returned to premenopausal levels after 15 yr from the menopause. In these women monocyte IL-1ra secretion was above the premenopausal range at all times after the menopause, but did not change with the passage of time since menopause. We conclude that hormone replacement decreases the in vitro secretion of both IL-1ra and IL-1 beta. The data also suggest that in normal women a progressive increase in the secretion of IL-1ra contributes to restore a normal IL-1/IL-1ra ratio after the menopause, a phenomenon which, in turn, may play a role in limiting postmenopausal bone loss.


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
R. H. Straub
The Complex Role of Estrogens in Inflammation
Endocr. Rev., August 1, 2007; 28(5): 521 - 574.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. Pfeilschifter, R. Koditz, M. Pfohl, and H. Schatz
Changes in Proinflammatory Cytokine Activity after Menopause
Endocr. Rev., February 1, 2002; 23(1): 90 - 119.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
E. Xiao, L. Xia-Zhang, M. Ferin, and S. L. Wardlaw
Differential Effects of Estradiol on the Adrenocorticotropin Responses to Interleukin-6 and Interleukin-1 in the Monkey
Endocrinology, July 1, 2001; 142(7): 2736 - 2741.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. J. Puder, P. U. Freda, R. S. Goland, and S. L. Wardlaw
Estrogen Modulates the Hypothalamic-Pituitary-Adrenal and Inflammatory Cytokine Responses to Endotoxin in Women
J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2403 - 2408.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Scheidt-Nave, H. Bismar, G. Leidig-Bruckner, H. Woitge, M. J. Seibel, R. Ziegler, and J. Pfeilschifter
Serum Interleukin 6 Is a Major Predictor of Bone Loss in Women Specific to the First Decade Past Menopause
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2032 - 2042.
[Abstract] [Full Text]


Home page
Physiol. Rev.Home page
J. E. Compston
Sex Steroids and Bone
Physiol Rev, January 1, 2001; 81(1): 419 - 447.
[Abstract] [Full Text] [PDF]


Home page
Biol Res NursHome page
E. J. Corwin
Understanding Cytokines Part II: Implications for Nursing Research and Practice
Biol Res Nurs, July 1, 2000; 2(1): 41 - 48.
[Abstract] [PDF]


Home page
Mol. Endocrinol.Home page
T. C. Spelsberg, M. Subramaniam, B. L. Riggs, and S. Khosla
The Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton
Mol. Endocrinol., June 1, 1999; 13(6): 819 - 828.
[Full Text]


Home page
CVIHome page
J. A. Bartlett, S. J. Schleifer, M. K. Demetrikopoulos, B. R. Delaney, S. C. Shiflett, and S. E. Keller
Immune Function in Healthy Adolescents
Clin. Vaccine Immunol., January 1, 1998; 5(1): 105 - 113.
[Abstract] [Full Text]


Home page
J. Appl. Physiol.Home page
E. M. Brooks, A. L. Morgan, J. M. Pierzga, S. L. Wladkowski, J. T. O'Gorman, J. A. Derr, and W. L. Kenney
Chronic hormone replacement therapy alters thermoregulatory and vasomotor function in postmenopausal women
J Appl Physiol, August 1, 1997; 83(2): 477 - 484.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1993 by The Endocrine Society